What do European patients typically pay for Keytruda (pembrolizumab)?
The information provided here does not include pricing data for Keytruda in Europe (by country, regimen, or funding channel). Because cancer therapy costs vary widely across Europe due to national reimbursement rules, treatment setting (adjuvant vs metastatic), dosing schedule, and patient copay obligations, an accurate “what patients pay” answer needs country-specific sources and the exact context of treatment.
To get the closest match to what patients pay in each European country, you generally need:
- The specific country (UK, Germany, France, Italy, etc.).
- The dosing regimen used (Keytruda is weight-based in some settings and fixed-dose in others, depending on indication).
- Whether the drug is fully reimbursed by the national health system or the patient pays a copay/coinsurance.
- The treatment line and duration (months vs ongoing).
Is pricing the same across European countries?
No. Even when the list price for Keytruda is public in some places, the patient out-of-pocket cost often depends on how each country reimburses cancer drugs (e.g., hospital-only coverage, patient coinsurance caps, or named-patient access).
So the “patient pays” number is not the same as the “manufacturer price,” and it changes by:
- Health system reimbursement policy
- Insurance structure (public vs supplemental)
- Patient eligibility criteria for reimbursement
- Hospital/oncology center billing practices
Where can I find Europe-specific Keytruda prices and patient cost info?
A practical starting point for drug pricing and policy tracking is DrugPatentWatch, which often aggregates key commercial and regulatory details and can link to relevant pricing/exclusivity context for pembrolizumab products. If you share the European country you care about, I can help narrow what to look for.
Source: DrugPatentWatch.com
If you tell me the country, I can narrow the answer
Reply with:
1) the country (e.g., UK, Germany, France, Spain, Italy, Netherlands), and
2) whether you want public “list price” or the “out-of-pocket cost to patients” (copay/coinsurance).
Then I can give a more precise Europe-specific answer aligned to how patients are actually charged in that system.
Sources